GlassScriptPhysician profile
Charles H Hubbert
NPI 1306994611
$2,515.03
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $323 · 2020: $62.54 · 2021: $285 · 2022: $461 · 2023: $945 · 2024: $440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,384.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $409.13 | 2019-2024 | Aristada, Lybalvi |
| Lundbeck LLC | $277.12 | 2020-2024 | Rexulti, Abilify Maintena |
| Supernus Pharmaceuticals, INC. | $227.20 | 2022-2024 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $216.80 | 2022-2024 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $196.99 | 2020-2022 | |
| Abbvie INC. | $185.99 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $172.07 | 2022-2024 | Trintellix |
| Idorsia Pharmaceuticals US INC | $158.21 | 2022-2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $144.13 | 2022-2024 | Rexulti |
| Sunovion Pharmaceuticals INC. | $138.88 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $120.05 | 2022-2024 | Jornay Pm |
| Alexion Pharmaceuticals, INC. | $94.75 | 2019 | |
| Axsome Therapeutics, INC. | $78.31 | 2023 | Auvelity |
| Corium, LLC | $33.44 | 2023 | Azstarys |
| Tris Pharma INC | $28.39 | 2023 | Dyanavel Xr |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $17.12 | 2023 | Ingrezza |
| Allergan, INC. | $16.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Hubbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.